LADX LadRx
- 3.120000
- +0.360000+13.04%
LadRx News
Xoma to Pay $1M to LadRx as Rare Disease Therapy Undergoes FDA Review
XOMA To Pay $1 Mln Milestone To LadRx As FDA Accepts Zevra's Arimoclomol NDA For NPC
LadRx Issues 2024 Update to Shareholders
FDA Acceptance of Arimoclomol Triggers $1 Million Payment LadRx Corporation (OTCQB:LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer
XOMA Acquires Drug Rights From LadRx for $5M
XOMA Acquires Royalty, Milestone Rights for Two Assets From LadRx
XOMA (XOMA) said Thursday it has acquired the royalty and milestone rights for two assets from LadRx for $5 million. The assets are arimoclomol, an investigational treatment for neurogenerative disord
Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 Oncology, Respectively
Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 O
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million With XOMA Corporation
XOMA acquires future milestone economics and royalties associated with arimoclomol and aldoxorubicin, allowing LadRx to focus on core LADR assetsLOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB:
Express News | LadRx Announces Reverse Stock Split Effective As Of May 17, 2023 >LADX
Express News | LadRx Announces Reverse Stock Split >LADX
LadRx, Oncology Drug Developer, Files for Nasdaq Uplisting, Public Offering
LadRx (NASDAQ:CYTR) Now Covered by StockNews.com
Stock analysts at StockNews.com assumed coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report released on Wednesday. The firm set a "hold" rating on the stock.LadRx Stock PerformanceLadRx
LadRx Highlights Patent Issued for Its LADR Technology
LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today hi
LadRx Announces Review of Strategic Alternatives and Provides Corporate Updates
LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announce
LadRx (NASDAQ:CYTR) Research Coverage Started at StockNews.com
Stock analysts at StockNews.com assumed coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a research note issued on Sunday. The firm set a "hold" rating on the stock.LadRx Price PerformanceLad
LadRx (OTCMKTS:CYTR) & MiNK Therapeutics (NASDAQ:INKT) Critical Contrast
LadRx (OTCMKTS:CYTR – Get Rating) and MiNK Therapeutics (NASDAQ:INKT – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on
StockNews.com Begins Coverage on LadRx (NASDAQ:CYTR)
StockNews.com started coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report released on Thursday. The brokerage issued a hold rating on the stock. LadRx Stock Performance LadRx has a 52-
LadRx (NASDAQ:CYTR) Coverage Initiated at StockNews.com
StockNews.com started coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report published on Tuesday morning. The brokerage issued a hold rating on the stock. LadRx Stock Performance LadRx h
Financial Analysis: Relay Therapeutics (NASDAQ:RLAY) Vs. LadRx (OTCMKTS:CYTR)
Relay Therapeutics (NASDAQ:RLAY – Get Rating) and LadRx (OTCMKTS:CYTR – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength
StockNews.com Initiates Coverage on LadRx (NASDAQ:CYTR)
Equities research analysts at StockNews.com began coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a research report issued to clients and investors on Monday. The brokerage set a "hold" rat
Critical Comparison: LadRx (OTCMKTS:CYTR) Vs. Quince Therapeutics (NASDAQ:QNCX)
LadRx (OTCMKTS:CYTR – Get Rating) and Quince Therapeutics (NASDAQ:QNCX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses bas
Analysis
Price Target
No Data
